[Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety].
To evaluate the efficacy and safety of combined use of methotrexate and meloxicam for treating of ankylosing spondylitis (AS), and to determine the optimal dosage of methotrexate. Thirty-two patients with AS were divided into group A (n=14) to receive oral methotrexate at the dose of 12.3+/-3.6 mg once a week and group B (n=18) at the dose of 21.3+/-3.2 mg once a week. Each of the patients in both groups also took oral meloxicam (7.5 mg) for 3 months. After treatment, the clinical indexes and inflammatory parameters of the patients significantly improved in both groups, with a total efficacy of 78.6% in group A and 88.9% in group B. The combination of methotrexate with meloxicam may achieve satisfactory results in AS treatment, which is not positively related to methotrexate dosage. In short-term usage, meloxicam does not increase the toxicity of methotrexate.